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ABSTRACT 
Background: Similar to the N-methyl-D-aspartate receptor antagonist ketamine, the 
metabotropic glutamate 2/3 receptor antagonist, MGS0039, shows antidepressant effects. 
However, there are no reports comparing these 2 compounds in the social defeat stress 
model of depression. 
Methods: We examined the effects of MGS0039 (1 mg/kg) and ketamine (10 mg/kg) on 
depression-like behavior in susceptible mice after repeated social defeat stress. Protein 
levels of brain-derived neurotrophic factor, TrkB, phospho-TrkB, α-amino-3-hydroxy-5- 
methyl-4-isoxazolepropionic acid receptor (GluA1), postsynaptic density protein 95, 
and dendritic spine density in selected brain regions were measured. 
Results: In the tail suspension and forced swimming tests, both MGS0039 and 
ketamine significantly attenuated the increased immobility time observed in susceptible 
mice, compared with vehicle-treated animals, 1 or 2 days after a single dose of drug. 
In the sucrose preference test, both compounds significantly improved the reduced 
preference typically seen in susceptible mice at 3 to 7 days after a single dose of drug. 
Western-blot analyses showed that similar to ketamine, MGS0039 significantly 
attenuated the reduced brain-derived neurotrophic factor, phospho-TrkB/TrkB ratio, 
GluA1 and postsynaptic density protein 95 seen in the prefrontal cortex, dentate gyrus, 
and CA3 of the hippocampus from susceptible mice, 8 days after a single dose. 
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Again, in a similar manner to ketamine, MGS0039 significantly attenuated the reduction 
of spine density in the prelimbic regions of the medial prefrontal cortex, dentate gyrus, 
and CA3 of the hippocampus, but not infralimbic regions of the medial prefrontal cortex 
and CA1, in susceptible mice 8 days after a single dose. In contrast, neither drug elicited 
an effect on altered brain-derived neurotrophic factor-TrkB signaling, GluA1, and 
postsynaptic density protein 95 levels and did not increase spine density observed in the 
nucleus accumbens of susceptible mice. 
Conclusions: Similar to ketamine, MGS0039 shows rapid and sustained antidepressant 
effects in the social defeat stress model. Long-lasting synaptogenesis in the prelimbic 
regions of medial prefrontal cortex, dentate gyrus, and CA3 might be implicated in this 
sustained antidepressant effect. 
Keywords: antidepressant, ketamine, metabotropic glutamate 2/3 (mGlu2/3) receptor 
antagonist, social defeat stress model, BDNF-TrkB signaling, synaptogenesis. 
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INTRODUCTION 
Depression is one of the most prevalent psychiatric disorders and the leading cause of 
disability worldwide. According to the World Health Organization, more than 350 
million individuals of all ages suffer from depression (World Health Organization, 
2016). Although current antidepressants are generally effective, the full therapeutic 
benefit of these therapies may require several weeks to bring about changes in mood 
and/or behavior. Additionally, approximately one-third of patients with depression fail 
to respond to current pharmacotherapy. Therefore, the development of new 
antidepressants effective in the treatment of resistant depression is urgently required 
(Chaki and Fukumoto, 2015; Hashimoto, 2015; Monteggia and Zarate, 2015). The 
N-methyl-D-aspartate (NMDA) receptor antagonist ketamine shows rapid and sustained 
antidepressant effects in depressed patients, including those with treatment-resistant 
disease (Berman et al., 2000; Zarate et al., 2006; Aan Het Rot et al., 2012; Singh et al., 
2016). Recent meta-analyses indicated that ketamine exhibited a greater potency of 
antidepressant effects compared with other NMDA receptor antagonists (Newport et al., 
2015; Kishimoto et al., 2016). In addition, others have reported rapid and long-lasting 
antidepressant-like effects for ketamine in animal models of depression (Yilmaz et al., 
2002; Maeng et al., 2008; Li et al., 2011; Ma et al., 2013; Yang et al., 2015a, 2016b; 
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Zhang et al., 2015b; Sun et al., 2016). Accumulating evidence suggests that 
metabotropic glutamate 2/3 (mGlu2/3) receptor antagonists, such as MGS0039 and 
LY341495, evoke antidepressant-like activities in rodents (Chaki et al., 2004; Karasawa 
et al., 2005; Yoshimizu et al., 2006; Pa1ucha-Poniewiera et al., 2010; Koike et al., 2011; 
Dwyer et al., 2012; Ago et al., 2013; Koike and Chaki, 2014; Fukumoto et al., 2016; 
Witkin et al., 2016). Furthermore, mGlu2/3 receptor antagonists have been reported to 
share similar efficacy in rodents and neural mechanisms with ketamine (Koike et al., 
2013a, 2013b), suggesting that mGlu2/3 receptor antagonists may have ketamine-like 
antidepressant actions. Although there is a report showing rapid and sustained 
antidepressant effects for LY341495 in a chronic unpredictable stress model (Dwyer et 
al., 2013), these effects have not been fully addressed in the context of synaptic 
plasticity. The purpose of this study was to compare the rapid and sustained 
antidepressant actions of MGS0039 and ketamine in the social defeat stress model. 
Additionally, we examined the effects of MGS0039 and ketamine on brain-derived 
neurotrophic factor (BDNF) – TrkB signaling, α-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA) receptors (GluA1), postsynaptic density protein 95 
(PSD-95), and dendritic spine density in brain regions thought to be implicated in 
ketamine’s antidepressant effects (Autry et al., 2011; Duman and Aghajanian, 2012; 
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Dwyer and Duman, 2013; Lepack et al., 2014; Zhou et al., 2014; Ohgi et al., 2015; Yang 
et al., 2015a, 2016b; Zhang et al., 2015b; Li et al., 2016; Bj.rkholm and Monteggia, 
2016). 
MATERIALS AND METHODS 
Animals 
Male adult C57BL/6 mice, aged 8 weeks (body weight 20–25 g, Japan SLC, 
Hamamatsu, Japan) and male adult CD1 (ICR) mice, aged 13 to 15 weeks (body weight 
>40 g, Japan SLC) were used for the social defeat stress model. Animals were housed 
under controlled temperatures and 12-h-light/-dark cycles (lights on between 7:00 am 
and 7:00 pm) with ad libitum food (CE-2; CLEA Japan, Tokyo, Japan) and water. This 
study was carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by the Chiba University Institutional Animal Care and Use 
Committee. 
Drugs 
MGS0039, synthesized at Taisho Pharmaceutical Co. Ltd. (Saitama, Japan), was 
dissolved in 1/15 M phosphate buffer (pH 8.0). Ketamine hydrochloride, prepared from 
Ketalar (Daiichi Sankyo Pharmaceutical, Tokyo, Japan) was dissolved in 1/15 M 
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phosphate buffer (pH 8.0). The doses of MGS0039 (1.0 mg/kg) and ketamine (10 
mg/kg) were used as previously reported (Chaki et al., 2004; Ago et al., 2013; Yang et 
al., 2015a; Zhang et al., 2015b). 
Social Defeat Stress Model 
The procedure of social defeat stress was performed as previously reported (Golden et 
al., 2011; Zhao et al., 2013; Yang et al., 2015a, 2016b; Zhang et al., 2015b). Every day 
the C57BL/6 mice were exposed to a different CD1 aggressor mouse for 10 minutes 
total for 10 days. When the social defeat session ended, the resident CD1 mouse and the 
intruder mouse were housed in one-half of the cage separated by a perforated Plexiglas 
divider to allow visual, olfactory and auditory contact for the remainder of the 24-hour 
period. At 24 hours after the last session, all mice were housed individually. On day 11, 
a social avoidance test was performed to identify subgroups of mice that were 
susceptible and unsusceptible to social defeat stress. This was accomplished by placing 
mice in an interaction test box (42 × 42 cm) with an empty wire-mesh cage (10 × 4.5 
cm) located at one end. The movement of the mice was tracked for 2.5 minutes, 
followed by 2.5 minutes in the presence of an unfamiliar aggressor confined in the 
wire-mesh cage. The duration of the subject’s presence in the interaction zone (defined 
as the 8-cm-wide area surrounding the wire-mesh cage) was recorded by a stopwatch. 
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The interaction ratio was calculated as the time spent in an interaction zone with an 
aggressor/time spent in an interaction zone without an aggressor. An interaction ratio of 
1 was set as the 
cutoff: mice with scores <1 were defined as susceptible to social defeat stress and those 
with scores ≥1 were defined as unsusceptible (Zhao et al., 2013). Only susceptible mice 
were used in the experiments. 
Behavioral Tests 
On day 12, vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) was 
injected i.p. (Figure 1a). All behavioral tests were performed in the following order: 
locomotion (30 minutes after injection), tail suspension test (TST) (24 hours after 
injection), forced swimming test (FST) (48 hours after injection), and 1% sucrose 
preference test (SPT) (3 and 7 days after injection) (Figure 1a). Mice were put into the 
test room 30 minutes before the behavioral tests. All tests were performed in a quiet 
room. After finishing all tests, mice were returned to the breeding room. The FST, TST, 
and SPT in mice are the most widely used behavioral assays for detecting potential 
antidepressant-like activity (Cryan and Holmes, 2005; Yang et al., 2015a; Zhang et al., 
2015a; 2015b; Dong et al., 2016; Ren et al., 2016). 
Locomotion 
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Locomotion was measured using the SCANET MV-40 (MELQUEST Co., Ltd., Toyama, 
Japan). This system consists of a black square cage (565 × 565 mm) equipped with 2 
crossing sensor frames of 72 (x axis) × 72 (y axis) pairs of near-infrared beam sensors, 
spaced 6 mm apart and at right angles to each other. The beam sensors thus form 2 
parallel horizontal grids set at different heights. A transparent Plexiglas cage (560 × 560 
× 330 mm) for the mouse was centered inside the system. Each pair of sensors was 
scanned every 0.1 seconds to detect animal movement. Two different variables of 
horizontal movements could be monitored by the lower sensors: small horizontal 
movements of 12 mm or more (M1; 1 U = 6 mm) and large horizontal movements of 
60 mm or more (M2; 1 U = 6 mm). The locomotion was performed under house lighting, 
and the movement of the cumulative distance was recorded for 60 minutes. The cage 
was cleaned between testing session. 
TST 
The mice were taken from their home cage, and a small piece of adhesive tape was 
placed approximately 2 cm from the tip of the tail. A single hole was punched in the 
tape and the mice were hung individually on a hook. The immobility time of each 
mouse was recorded for 10 minutes. All mice were videoed, and then the immobility 
time of tail suspension was scored by a skilled observer who used stopwatch. Mice were 
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considered immobile only when they hung passively and completely motionless. 
 
Figure 1. Schedule of social defeat stress, treatment, and behavioral tests.a: The schedule of social 
defeat stress (10 days), drug treatment, and behavioral tests. Social defeat stress was performed from 
day 1 to day 10. Social interaction test was performed on day 11. Vehicle (10 mL/kg), MGS0039 (1 
mg/kg), or ketamine (10 mg/kg) was administered i.p into susceptible mice on day 12. Locomotion 
test (LMT), tail suspension test (TST), and forced swim test (FST) were performed 0.5, 24, and 48 
hours after a single injection, respectively. A 1% sucrose preference test (SPT) was performed 3 day 
(day 15) and 7 days (day 19) after a single injection. (b) The schedule of social defeat stress (10 days), 
drug treatment, and collection brain samples for western blot. Social interaction test was performed on 
day 11. Vehicle (10 mL/kg), MGS0039 (1 mg/kg), or ketamine (10 mg/kg) was administered i.p into 
susceptible mice on day 12. Brain samples were collected on day 20. (c) The schedule of social defeat 
stress (10 days), drug treatment, and collection brain samples for Golgi staining. Social interaction test 
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was performed on day 11. Vehicle (10 mL/kg), MGS0039 (1 mg/kg), or ketamine (10 mg/kg) was 
administered i.p into susceptible mice on day 12. Brain samples were collected on day 20. Ket, 
ketamine; MGS, MGS0039; Veh, vehicle. 
FST 
The mice were placed individually in a cylinder (diameter: 23 cm, height: 31 cm) 
containing 15 cm of water maintained at 23 ± 1°C. The animals were not able to touch 
the bottom of the cylinder. Animals were tested in an automated forced-swim apparatus 
by the SCANETMV-40 (MELQUEST Co., Ltd., Toyama, Japan). The cylinder was 
placed in a box with infrared cell sensors on the walls to detect swimming activity. The 
software set up a rectangle that circumscribed the body of an animal every 0.3 seconds. 
If the animals were out of the rectangle (i.e., a part of the animal body was detected 
outside the rectangle) 0.3 seconds after setting up the rectangle, the software counted as 
“movement (swimming)” in that period. Immobility was defined as such if the animal 
stayed within the same rectangle 0.3 seconds after setting up the rectangle. Immobility 
time was calculated from activity time as (total) −(active) time by using analysis 
software of the apparatus. Cumulative immobility time was scored for 6 minutes during 
the test. 
SPT 
Mice were exposed to water and 1% sucrose solution for 48 hours, followed by 4 hours 
of water and food deprivation and 1 hour exposure to 2 identical bottles: one was water 
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and the other was 1% sucrose solution. The bottles containing water and sucrose were 
weighed before and at the end of this period and the sucrose preference was determined. 
Western-Blot Analysis 
Eight days after vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or ketamine (10 mg/kg) 
injection, the brain samples of prefrontal cortex (PFC), nucleus accumbens (NAc), 
dentate gyrus (DG), and CA1 and CA3 of the hippocampus were collected, since these 
brain regions are implicated in depression-like phenotype as described previously (Yang 
et al., 2015a, 2016b; Zhang et al., 2015a; Ren et al., 2016) (Figure 1b). Basically, tissue 
samples were homogenized in Laemmli lysis buffer. Aliquots (10 μg) of protein were 
measured using the DC protein assay kit (Bio-Rad, Hercules, CA) and incubated for 5 
minutes at 95°C, with an equal volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol, 
0.1% bromophenol blue, 10% β-mercaptoethanol, and 4% sodium dodecyl sulfate and 
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis, using 10% 
mini-gels (Mini-PROTEAN TGX Precast Gel; Bio-Rad). Proteins were transferred onto 
polyvinylidene difluoride membranes using a Trans Blot Mini Cell (Bio-Rad). For 
immunodetection, the blots were blocked with 2% bovine serum albumin in Tris 
buffered saline + 0.1 % Tween 20 (TBST) for 1 hour at room temperature (RT) and kept 
with primary antibodies overnight at 4°C. The following primary antibodies were used: 
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BDNF (1:1000, Santa Cruz Biotechnology, Inc.), phosphorylated-TrkB (Tyr 706) (1:200, 
Santa Cruz Biotechnology), and TrkB (80E3) (1:1000, Cell Signaling Technology), 
AMPA glutamate receptor 1 (GluA1) (1 μg/mL, Abcam, Cambridge, MA), and PSD-95 
(1 μg/mL, Invitrogen, Carlsbad, CA). The next day, the blots were washed 3 times in 
TBST and incubated with horseradish peroxidase-conjugated anti-rabbit antibody 
(1:5000) for 1 hour at RT. After 3 final washes with TBST, the bands were detected 
using enhanced chemiluminescence plus the Western Blotting Detection system (GE 
Healthcare Bioscience). The blots then were washed 3 times in TBST and incubated 
with the primary antibody directed against β-actin. Images were captured with a Fuji 
LAS3000-mini imaging system (Fujifilm, Tokyo, Japan) and immunoreactive bands 
were quantified. 
Golgi Staining 
Golgi staining was performed using the FD Rapid Golgi Stain TM Kit (FD Neuro 
Technologies, Inc., Columbia, MD) following the manufacturer’s instructions. Eight 
days after a single administration of vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or 
ketamine (10 mg/kg), mice were deeply anesthetized with sodium pentobarbital, and 
brains were removed from the skull and rinsed in double distilled water (Figure 1c). 
Brains were immersed in the impregnation solution, made by mixing equal volumes of 
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Solution A and B, overnight and then stored in fresh solution for 2 weeks in the dark. 
Brains were transferred into Solution C overnight and then stored in fresh solution at 
4°C for 1 week in the dark. Coronal brain sections (100-μm thickness) were cut on a 
cryostat (3050S, Leica Microsystems AG, Wetzlar, Germany) with the chamber 
temperature set at -20°C. Each section was mounted in Solution C on saline-coated 
microscope slides. After absorption of excess solution, sections were dried naturally at 
RT. Dried sections were processed following the manufacturer’s instructions. Briefly, 
images of dendrites within DG, CA1, and CA3 of the hippocampus, mPFC and NAc 
were captured using a 100× objective with a Keyence BZ-9000 Generation microscope 
(Osaka, Japan). Spines were counted along DG, CA1, CA3, mPFC, and NAc dendrites 
starting from their point of origin from the primary dendrite, as previously reported 
(Yang et al., 2015a, 2016b; Zhang et al., 2015a). For spine density measurements, all 
clearly evaluable areas containing 50 to 100 μm of secondary dendrites from each 
imaged neuron were used. To determine relative spine density, spines on multiple 
dendritic branches from a single neuron were counted to obtain an average spine 
number per 10 μm. For spine number measurements, only spines that emerged 
perpendicular to the dendritic shaft were counted. Three neurons per section, 3 sections 
per animal, and 6 animals were analyzed. The average value for each region in each 
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individual was obtained. These individual averages were then combined to yield a grand 
average for each region. 
Statistical Analysis 
The data show as the mean ± SEM. Analysis was performed using PASW Statistics 20 
(formerly SPSS Statistics; SPSS). Comparisons between groups were performed using 
the 1-way ANOVA followed by posthoc Tukey test. P < .05 was considered statistically 
significant. 
RESULTS 
MGS0039 Shows Rapid-Acting and Long-Lasting Antidepressant Effects as 
Ketamine in the Social Defeat Stress Model 
Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild 
stress model (Li et al., 2011; Ma et al., 2013; Liu et al., 2016; Sun et al., 2016) and 
social defeat stress model (Yang et al., 2015a, 2016b; Zhang et al., 2015b). We 
examined whether MGS0039 showed rapid-acting and long-lasting antidepressant 
effects in the social defeat stress model. Vehicle, MGS0039 (1.0 mg/kg), or ketamine 
(10 mg/kg) was injected i.p. into the susceptible mice after social defeat stress (Figure 
1a). Locomotion showed no difference (F3, 35 = 1.240, P = .311) among the 4 groups 
(Figure 2a). In the TST and FST, MGS0039 and ketamine significantly attenuated an 
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increased immobility time in the susceptible mice (Figure 2b-c). One-way ANOVA 
 
Figure 2. Antidepressant effects of MGS0039 and ketamine in the social defeat mice. (a) 
Locomotion test (LMT). (b) Tail suspension test (TST). (c) forced swim test (FST). (d-e) 1% sucrose 
preference test (SPT). The values represent the mean ± SEM (n = 9). *P < .05, **P < .01, ***P 
< .001 compared with the vehicle + stress group. Ket, ketamine; MGS, MGS0039; Veh, vehicle. 
detected statistical significance in both the TST and FST (TST: F3, 35 = 4.661, P 
= .008; FST: F3, 35 = 8.315, P < .001) among the 4 groups (Figure 2b-c). In the SPT, 
preference of mice after an injection of MGS0039 or ketamine was significantly higher 
(e: day 15, F3, 35 = 60.378, P < .001, f: day 19, F3, 35 = 5.511, P = .004) than that of 
the vehicletreated group (Figure 2d-e). These behavioral data suggest that MGS0039 
promotes rapid and long-lasting antidepressant effects in the social defeat stress model, 
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consistent with ketamine’s antidepressant-like effect.  
Effects of MGS0039 and Ketamine on Alterations in BDNF-TrkB Signaling and 
Synaptogenesis in the Selected Brain Regions 
We performed western-blot analyses of BDNF, TrkB, phosphorylated TrkB (p-TrkB), 
GluA1, and PSD-95 in selected brain regions (PFC, NAc, DG, CA1, and CA3 of the 
hippocampus) 8 days after a dose of vehicle (10 mL/kg), MGS0039 (1.0 mg/kg), or 
ketamine (10 mg/kg) (Figure 1b). Social defeat stress significantly decreased levels of 
BDNF protein in the PFC, DG, and CA3, but not CA1, while significantly increased 
BDNF protein in the NAc. MGS0039 significantly attenuated reduced levels of BDNF 
protein in the PFC and DG of susceptible mice after social defeat stress, although 
ketamine significantly attenuated reduced levels of BDNF protein in the PFC, DG, and 
CA3 (Figure 3a). In contrast, 2 compounds did not alter the increased BDNF levels in 
the NAc (Figure 3a). One-way ANOVA detected statistical significance in BDNF 
protein (PFC: F3, 23 = 18.190, P < .001; NAc: F3, 23 = 9.129, P = .001; DG: F3, 23 = 
8.274, P = .001; CA1: F3, 23 = 0.086, P = .967; CA3: F3, 23 = 12.408, P < .001) among 
the 4 groups (Figure 3a). To clarify the role of TrkB phosphorylation in the action of 
MGS0039 and ketamine, we performed western-blot analyses of TrkB and p-TrkB, an 
activated form of TrkB, in samples from PFC, NAc, DG, CA1, and CA3. Social defeat 
19 
 
stress significantly decreased the ratio of p-TrkB/TrkB in the PFC, CA3, and DG, but 
not CA1, while significantly increased the ratio of p-TrkB/TrkB in the NAc. MGS0039 
significantly attenuated the reduced ratio of p-TrkB/TrkB in the CA3 of susceptible 
mice after social defeat stress, although ketamine significantly attenuated the reduced 
ratio of p-TrkB/TrkB in the PFC, DG, and CA3 (Figure 3b). Oneway ANOVA revealed 
statistical significance in p-TrkB/TrkB (PFC: F3, 23 = 4.360, P = .016; NAc: F3, 23 = 
3.715, P = .028; DG: F3, 23 = 4.168, P = .020; CA1: F3, 23 = 0.337, P = .799; CA3: F3, 
23 = 6.889, P = .002) among the 4 groups (Figure 3b). In contrast, 2 compounds did not 
alter the increased ratio of p-TrkB/TrkB in the NAc. These findings suggest that BDNF–
TrkB signaling in the PFC, CA3, and DG of hippocampus might be involved in the 
antidepressant mechanisms of MGS0039 and ketamine. Proteins such as GluA1, a 
subtype of the AMPA receptor, and PSD-95 are markers for synaptogenesis (Duman and 
Aghajanian, 2012; Ohgi et al., 2015). Social defeat stress significantly decreased the 
levels of GluA1 in PFC, DG, and CA3, but not CA1, while significantly increased 
GluA1 protein in the NAc. Furthermore, MGS0039 significantly attenuated the 
reduction of GluA1 in the PFC and DG, although ketamine significantly attenuated the 
reduction of GluA1 in the PFC, DG, and CA3 (Figure 3c). One-way ANOVA revealed 
statistical significance in GluA1 protein (PFC: F3, 23 = 22.322, P < .001; NAc: F3, 23 = 
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6.834, P = .002; DG: F3, 23 = 17.683, P < .001; CA1: F3, 23 = 0.944, P = .438; CA3:  
 
Figure 3. Effects of MGS0039 and ketamine on the brain-derived neurotrophic factor (BDNF) and 
TrkB phosphorylation in the brain regions. (a) Expression of BDNF in the brain regions. (b) Ratio of 
phosphorylated TrkB (p-TrkB) to total TrkB in the brain regions. (c) Expression of GluA1 in the 
brain regions. (d) Expression of postsynaptic density protein 95 (PSD95) in the brain regions. The 
value was expressed as a percentage of that of control mice. The values represent the mean ± SEM 
(n = 5 or 6). *P < .05, **P < .01, ***P < .001 compared with the vehicle + stress group. Ket, 
ketamine; MGS, MGS0039; Veh, vehicle. 
F3, 23 = 4.496, P = .014) among the 4 groups (Figure 3c). In contrast, MGS0039 and 
ketamine did not alter the increased levels of GluA1 in NAc (Figure 3c). Social defeat 
stress significantly decreased the levels of PSD-95 in the PFC, DG, and CA3, but not 
CA1, while significantly increased PSD-95 protein in the NAc. Furthermore, MGS0039 
significantly attenuated the reduction of PSD-95 in the PFC and DG, although ketamine 
significantly attenuated the reduction of PSD-95 in the PFC, DG, and CA3 (Figure 3d). 
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One-way ANOVA detected statistical significance in PSD-95 protein (PFC: F3, 23 = 
3.611, P = .031; NAc: F3, 23 = 5.232, P = .008; DG: F3, 23 = 15.554, P < .001; CA1: 
F3, 23 = 0.428, P = .735; CA3: F3, 23 = 7.270, P = .002) among the 4 groups (Figure 
3d). In contrast, MGS0039 and ketamine did not alter the increased levels of PSD-95 in 
NAc (Figure 3d). 
Effects of MGS0039 and Ketamine on Alterations in Dendritic Spine Density in the Selected 
Brain Regions After Social Defeat Stress 
Social defeat stress causes alterations in dendritic spine density in the medial PFC (mPFC), CA3 and 
DG of the hippocampus, and NAc (Jiang et al., 2015; Zhang et al., 2015b; Yang et al., 2015a, 2016b). 
In this study, we examined whether MGS0039 (1.0 mg/kg) and ketamine (10 mg/kg) could affect 
alterations in the dendritic spines of the prelimbic (PrL) and infralimbic (IL) regions of mPFC, shell 
and core of the NAc, and DG, CA1, and CA3 of the hippocampus after social defeat stress. We 
found significant differences in the PrL of mPFC, NAc core, NAc shell, DG and CA3, but not IL of 
mPFC and CA1 (Figure 4). Social defeat stress significantly decreased dendritic spine density in the 
PrL of mPFC, DG, and CA3. Both MGS0039 and ketamine significantly attenuated the reduced 
spine density seen in the PrL, DG, and CA3 from mice with depression-like phenotype, 8 days after 
a single dose (Figure 4a, e, g). In contrast, social defeat stress significantly increased dendritic spine 
density in the NAc core and NAc shell. Neither MGS0039 nor ketamine altered spine density in the 
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NAc of susceptible mice (Figure 4c-d). One-way ANOVA showed statistical significance for all of 
 
Figure 4. Effects of MGS0039 and ketamine on alterations in dendritic spine density in the brain 
regions after social defeat stress. (a) Prelimbic region (PrL) of medial prefrontal cortex (mPFC). (b) 
Infralimbic region (IL) of mPFC. (c) nucleus Accumbens (NAc) core. (d) NAc shell. (e) Dentate 
gyrus (DG). (f) CA1. (g) CA3. Scale bar = 10 μm. Values represent the mean ± SEM (n = 6). 
Representative photomicrographs of Golgi-Cox stained pyramidal neurons in the selected brain 
regions from animals of each group. ***P < .001 compared with the vehicle + stress group. Ket, 
ketamine; MGS, MGS0039; Veh, vehicle. 
the examined regions (PrL: F3, 23 = 64.64, P < .001; IL: F3, 23 = 0.528, P = .668; NAc core: F3, 23 
= 68.45, P < .001; NAc shell: F3, 23 = 62.44, P < 0.001; DG: F3, 23 = 59.75, P < .001; CA1: F3, 23 
= 1.652, P = .209; CA3: F3, 23 = 77.53, P < .001). These findings suggest the role of the PrL of 
mPFC, DG, and CA3, but not IL of mPFC, NAc, and CA1, in the mechanistic action of MGS0039 
and ketamine. 
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DISCUSSION 
In this study, we found that similar to ketamine, a single dose of MGS0039 promoted 
rapid and prolonged antidepressant effects in the social defeat stress model. Interestingly, 
it evoked an antidepressant response 7 days after a single dose in a comparable manner 
to ketamine (Zhang et al., 2015b). Previous studies showed that, 7 days after a single 
dose, ketamine could ameliorate anhedonia in rodents under the chronic mild stress 
model (Li et al., 2011; Ma et al., 2013). Therefore, it is noteworthy that these rapid and 
long-lasting antidepressant effects for MGS0039 in the social defeat stress model bear 
similarity to the therapeutic effects of ketamine in chronic mild stress or social defeat 
stress models (Li et al., 2011; Ma et al., 2013; Yang et al., 2015a, 2016b; Zhang et al., 
2015b). Since ketamine also shows rapid and sustained antidepressant actions in 
patients with treatmentresistant depression, it is feasible that MGS0039 could promote 
analogous actions in depressed patients. Because MGS0039 has been reported to be a 
selective mGlu2/3 receptor antagonist (Chaki et al., 2004) and to exhibit both 
antidepressant and anxiolytic effects (Chaki et al., 2004; Yoshimizu et al., 2006) at a 
dose used in this study, the effect of MGS0039 is mediated through blockade of 
mGlu2/3 receptor. Moreover, since MGS0039 did not alter general behavioral including 
locomotion at this dose, it is unlikely that the effect of MGS0039 is attributable to 
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change in general behaviors. We previously reported conspicuous reductions in the level 
of BDNF in the PFC, DG, and CA3, but not CA1, of mice susceptible to social defeat 
stress (Yang et al., 2015a, 2016; Zhang et al., 2015b) and learned helplessness rats 
(Shirayama et al., 2015; Yang et al., 2015a, 2016a). In this study, we also noted reduced 
levels of BDNF in the PFC, DG, CA3, but not CA1, of susceptible mice after social 
defeat stress, but increased BDNF levels in the NAc (Zhang et al., 2015b; Shirayama et 
al., 2015; Yang et al., 2015a). Furthermore, we identified that social defeat stress caused 
decreased phosphorylation of TrkB in the PFC, DG, and CA3 and increased 
phosphorylation in the NAc. Thus, it is probable that social defeat stress attenuated 
BDNF–TrkB signaling in PFC and hippocampus (DG and CA3) but increased signals in 
the NAc, resulting in depression-like behavior in rodents. Compellingly similar to 
ketamine, MGS0039 significantly lessened the reduction of BDNF in the PFC, DG, and 
CA3, although it had no effect on the increased BDNF levels seen in the NAc of 
susceptible mice. Given the role of BDNF–TrkB signaling in the depression-like 
phenotype (Nestler et al., 2002; Duman and Monteggia, 2006; Hashimoto, 2010, 2013), 
just like ketamine, MGS0039 may promote rapid and sustained antidepressant effects by 
normalizing BDNF levels in the PFC and hippocampus (DG and CA3). This assumption 
is supported by a previous report that the mGlu2/3 receptor antagonist, LY341495, 
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exerts its antidepressant effect through stimulation of TrkB signaling (Koike et al., 
2013a). Tracking dendritic morphology, we found opposing changes in spine density 
between the mPFC, hippocampus, and NAc after social defeat stress. The reduced spine 
density found in the PrL of mPFC, DG, and CA3 matches the findings seen in rodents 
under the unpredictable chronic mild stress, inflammation, and learned helplessness 
models (Li et al., 2011; Shirayama et al., 2015; Zhang et al., 2015a, 2015b; Yang et al., 
2015b, 2016b). In contrast, we found increased spine density in the NAc of depressed 
mice after social defeat stress, consistent with results from the inflammation and learned 
helplessness models (Zhang et al., 2015a; Yang et al., 2015b, 2016b). Moreover, in 
keeping with ketamine, MGS0039 attenuated the reduced spine density observed in the 
PrL of mPFC, DG, and CA3, although it had no impact on the increased spine density 
found in the core and shell of the NAc. Considering the function of synaptogenesis in 
the action of antidepressants (McEwen, 2007; Duman and Aghajanian, 2012; Ohgi et al., 
2015), it is likely that the PrL region of the mPFC, DG, and CA3 of the hippocampus 
are involved in this drug’s action. It should be noted that another mGlu2/3 receptor 
antagonist, LY341495, elevated synthesis of synaptic proteins in the PFC (Dwyer et al., 
2012), strengthening the argument that increased synaptogenesis in the PFC may 
underpin the antidepressant actions of mGlu2/3 receptor antagonists. In addition, local 
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injection of LY341495 into the mPFC exerts antidepressant effects (Fukumoto et al., 
2016), indicating the role of the mPFC in the antidepressant action of mGlu2/3 receptor 
antagonists. In conclusion, this study shows that like ketamine, MGS0039 can produce 
rapid and sustained antidepressant effects in the social defeat stress model. Furthermore, 
it is likely that increased synaptogenesis in the PrL of mPFC and DG and CA3 of the 
hippocampus after a single dose of MGS0039 may promote this prolonged 
antidepressant response. Therefore, mGlu2/3 antagonists such as MGS0039 can act as 
rapid and sustained therapeutic agents for patients with depression, although efficacy 
and safety of mGlu2/3 receptor antagonists need to be proven in a clinical setting. 
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